Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.

Trial Details

NCT ID

NCT06221553

Phase

PHASE1

Sponsor

Chulalongkorn University

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

B7H3 specific CAR T cell with IL-7Ra signaling domain

Locations (sample)

Bangkok, Pathumwan, Thailand|13.75398,100.50144

Key Eligibility Criteria

Participants must have diffuse intrinsic pontine glioma at any timepoint following completion of standard radiotherapy
Age 1-18 years
Sex: Male or female
CNS reservoir catheter, such as an Ommaya or Rickham catheter, present in the proper location for CNS-directed therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →